A top 20 global biopharma launching a new class of biologics with six assets across multiple therapeutic areas over two to five years, into a hyper-competitive and highly uncertain marketplace.
Six assets, multiple therapeutic areas, one franchise P&L, and a marketplace moving faster than any five-year plan could assume. The work was to make the plan hold anyway.
There is no consulting partner who could have achieved what you did, in the time frame you had, with the budget we had. You are exceptional.
If your organization is launching a new therapy where failure is not an option, let’s talk.
Start a conversation